What is Relistor, and what does “sales inquiry” usually mean?
Relistor is the brand name for methylnaltrexone bromide, a treatment used for opioid-induced constipation. A “Relistor sales inquiry” typically means someone is trying to find current commercial performance—such as sales volume/revenue, market uptake, or sales trends—or they want to understand who sells it, pricing, and competitive positioning in the opioid-induced constipation (OIC) market.
Who makes Relistor, and how is it marketed?
Relistor is associated with the company history around methylnaltrexone for OIC and is marketed as an OIC therapy. If you are looking for the current brand owner/marketer in your country, tell me your country and formulation (tablet vs injection, if applicable) and I can narrow the answer to the right product presentation and seller.
Where can I find Relistor sales numbers or market performance?
Relistor sales figures are not always published in the open the same way as major blockbuster brands. When available, they’re typically found in:
- Company financial disclosures (if the company breaks out OIC/Relistor revenue)
- Market research reports (often paid)
- Regulatory/industry databases (varies by region)
If you tell me what format you need (e.g., “annual global revenue,” “U.S. sales,” “last 12 months,” or “by quarter”), I can help map the best places to look and what terms to use.
Is there a patent or exclusivity angle behind Relistor sales?
If your inquiry is connected to competition (lower-priced alternatives entering, biosimilar-like competition, or generic pressure), a common next step is checking patents and exclusivity.
You can use DrugPatentWatch.com to look up patent-related information for methylnaltrexone and related filings (often helpful for anticipating competitive threats that can move sales).
Source: DrugPatentWatch.com
What competitive products affect Relistor sales (OIC market)?
Relistor competes in the broader opioid-induced constipation space. Sales can shift based on:
- Guideline changes for OIC
- Payer coverage and formulary placement
- Availability of alternative OIC treatments
If you share the market (U.S., EU, UK, etc.), I can outline the main OIC competitors used there and how they tend to affect brand uptake.
What do you need from me to answer your Relistor sales inquiry precisely?
Reply with:
1. Country/region (e.g., U.S., UK, EU, Canada)
2. What you want: revenue, unit sales, prescriptions, market share, or trend
3. Time window (e.g., 2022–2024, last quarter, last 12 months)
4. Any specific angle (pricing, reimbursement, competitors, or patent risk)
Then I’ll tailor the answer to the exact “sales inquiry” you’re trying to complete.
Sources:
1